R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - I. Biochemical Profile In Vitro

Abstract

SummaryR 68 070 or (E)-5-[[[(3-pyridinyl)[3-(trifluoromethyl)phenyl]- methylen]amino]oxy] pentanoic acid (Janssen Research Foundation, Belgium) combines specific thromboxane A2 (TXA2) synthetase inhibition with TXA2/prostaglandin endoperoxide receptor blockade in one molecule.In vitro, the compound specifically inhibits the production of TXB2 from [14C] arachidonic acid by washed human platelets (IC50 = 8.2 × 10-9 M) and by platelet microsomes (IC50 = 3.6 × 10-9 M), of MDA (IC50 = 1.91 × 10-8 M) and of TXB2 (IC50 = 1.47 × 10-8 M) by thrombin-coagulated human platelet-rich plasma (P.R.P.) and whole blood respectively and increases the levels of PGD2, PGE2, PGF2α and 6-keto-PGF1α. The activity of cyclo-oxygenase-, prostacyclin synthetase-, 5-, 12- and 15-lipoxygenase-enzymes are not affected. Additionally, R 68 070 inhibits human platelet aggregation in P.R.P. induced by U 46619 3 × 10-7 M to 2 × 10-6 M (IC50 = 2.08 × 10-6 M to 2.66 × 10-5 M), collagen 0.5 to 2 μg/ml (IC50 = 2.85 × 10-6 M to 4.81 × 10-5 M), arachidonic acid 7.5 × 10-4 M to 2 × 10- M (IC50 = 2.1 × 10-8 M to 3.3 × 10-8 M) and the U 46619 (1 × 10-7 M)-induced accumulation of [32P] phosphatidic acid (IC50 = 5.24 × 10-7 M) in washed human platelets. Collagen (0.75 μg/ml)-induced ATP release (IC50 = 4.1 × 10-6 M), ADP (1 to 2.5 × 10-6 M)-induced second wave aggregation (IC50 = 3.19 × 10-6 M) in P.R.P. as well as the collagen (1 μg/ml)-induced adhesion/aggregation reaction in human whole blood (IC50 = 1.02 × 10-5 M) are reduced as well by the compoun.Primary platelet reactions induced by serotonin, ADP, PAF, or A 23187, platelet adenylate cyclase- and cAMP phosphodiesterase-activity, and platelet inhibitory activities of PGD2, PGI2, PGE2, PGE1 are not modified by R 68 070.This biochemical profile is compatible with a dual mechanism of action of R 68 070, namely TXA2 synthetase inhibition at low concentrations, plus additionally TXA2/prostaglandin endoperoxide receptor blockade at higher concentrations

Thromboxane A synthase-independent production of 12-hydroxyheptadecatrienoic acid, a BLT2 ligand

“…However, the therapeutic effects of these agents have been disappointing ( 32 ), partly because inhibition of TxAS also results in accumulation of PGH 2 , which can activate TP receptors at higher concentrations ( 30 ). Although dual inhibition of TxAS and TP may be a potential treatment option ( 33 ), the unexpected production of PGs observed in this study might evoke some side effects associated with TxAS inhibitors, including headache and fever. Lipidomics analysis using LC-MS/MS will be a Fig.…”

Ridogrel: An Antiplatelet Agent with Antihypertensive Properties

“…It is a weak acid, nearly insoluble in water but soluble in organic solvents (9). As might be expected, it is highly bound to albumin; indeed, the presence of plasma proteins reduces its activity by about 100 fold (9).…”

Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury.

“…Seven of the dogs did not receive any treatment and served as controls. Another 17 dogs received the antiplatelet agents ridogrel (a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist; Janssen Pharmaceuticals) (19) and either ketanserin (a serotonin S2 receptor antagonist; Janssen Pharmaceuticals) (20) or LY53857 (another serotonin receptor antagonist; Eli Lilly) (21). Of these antiplatelet agenttreated dogs, 7 received bolus doses of ridogrel at 5 mg/kg and either ketanserin at 0.5 mg/kg or LY53857 at 0.2 mg/kg every 8-12 hr for 7-14 days through catheters positioned in the left atrium.…”